Ghost Tree Capital’s Sarepta Therapeutics SRPT Stock Holding History

Ghost Tree Capital’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-150,000	Closed	-$18.2M	–	73
2023 Q3	$18.2M	Buy	+150,000	New	+$17M	5.98%	3
2023 Q2	–	Sell	-125,000	Closed	-$17.2M	–	68
2023 Q1	$17.2M	Buy	+125,000	New	+$16.2M	5.09%	3
2017 Q1	–	Sell	-200,000	Closed	-$5.49M	–	80
2016 Q4	$5.49M	Sell	200,000 -150,000	-43%	-$6.02M	1.32%	36
2016 Q3	$21.5M	Buy	350,000 +250,000	+250%	+$7.56M	3.49%	5
2016 Q2	$1.91M	Buy	+100,000	New	+$1.85M	0.55%	45

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Ghost Tree Capital's SRPT Position: Q3 2024 in Review

Ghost Tree Capital increased its Sarepta Therapeutics (SRPT) stake by 118% in Q3 2024, buying an estimated $8.99M and bringing the position to 120,000 shares worth $15M. The position accounts for 4.53% of the portfolio, ranked #3.

Ghost Tree Capital first reported a position in SRPT in Q3 2015 and has held it in 26 quarters since. The position peaked at $44.1M in Q2 2019. 457 funds tracked by Wall St. Rank hold SRPT as of Q3 2024.

Ghost Tree Capital held 120,000 shares of Sarepta Therapeutics worth $15M as of Q3 2024.
Ghost Tree Capital bought 65,000 Sarepta Therapeutics shares in Q3 2024, an estimated $8.99M.
Sarepta Therapeutics made up 4.53% of Ghost Tree Capital's portfolio in Q3 2024, its #3 holding.
Ghost Tree Capital first reported a position in Sarepta Therapeutics in Q3 2015 and has held it in 26 quarters since.
Ghost Tree Capital's Sarepta Therapeutics position peaked at $44.1M in Q2 2019.
457 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2024.

Based on Ghost Tree Capital's 13F filing for Q3 2024, filed 14 Nov 2024.